Tripartite Compounds Inhibiting SREBP Proteolysis for Metabolic Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are inadequate for treating metabolic disorders such as obesity and cancer, as they lack effective compositions and methods to inhibit the SREBP pathway, which is crucial for regulating fat metabolism and cholesterol synthesis.
Innovation Solution
Development of compounds with specific chemical structures that inhibit the SREBP pathway by impairing the proteolytic activation of SREBPs, thereby reducing the transcription of genes involved in cholesterol and fatty acid biosynthesis, including fatostatin A and its analogs, which are administered to treat metabolic disorders and cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional methods are used to treat metabolic disorders, then treatment options are limited, but effectiveness is insufficient
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of fatostatin A to create analogs with different pharmacological properties. Specifically, the patent explores various substituents and structural modifications that can alter the binding affinity, selectivity, and metabolic profile of the compound, thereby improving treatment effectiveness while expanding treatment options for different metabolic disorders and cancer types.
2Object-generated harmful factors
If SREBP pathway inhibition is achieved, then fat metabolism and cholesterol synthesis are reduced, but potential side effects increase
Solution Approach 1:
The patent applies local quality by creating selective inhibitors that target specific aspects of the SREBP pathway. Through structural modifications of fatostatin A, the patent aims to achieve selective inhibition of lipogenic enzymes while minimizing off-target effects. This involves optimizing the compound's interaction with specific SREBP isoforms and downstream target genes to reduce harmful effects while maintaining therapeutic effectiveness.
Solution Approach 2:
The patent uses copying by creating analogs of fatostatin A that replicate its core inhibitory function while modifying specific structural features. These analogs copy the essential pharmacological activity of blocking SREBP activation but with improved safety profiles or enhanced selectivity, thereby reducing adverse effects while maintaining pathway inhibition effectiveness.
Data Source
AI summary
The present invention relates to methods of treating a disease related to cell hyper-proliferation via administration of a therapeutically effective amount of a compound having a general tripartite structure A-B-C. In the tripartite structure A, B, and C are identical or non-identical structures, for example, but not limited to, heterocyclic, phenyl or benzyl ring structures with or without substitutions and are described in detail herein. The methods may utilize particular compounds, for example, having a piperidinyl, a pyrrolinyl or pyridinyl A ring, a thiazole B ring, and a phenyl C ring which may be further substituted independently.